Abbott has finalized its acquisition of Exact Sciences, positioning itself as a leader in the rapidly growing cancer screening and diagnostics market. This move expands Abbott's reach in early cancer detection and personalized treatment, adding key products like Cologuard and Oncotype DX to its portfolio. The acquisition supports Abbott's goal to advance preventative and personalized healthcare, tapping into a $60 billion U.S. cancer diagnostics market. Exact Sciences is now a wholly owned subsidiary, with its shares delisted from Nasdaq as of March 20, 2026.
Abbott has introduced Ensure Max Protein 3-in-1 Muscle Support, a powder combining 30g of protein, 5g of creatine monohydrate, and 3g of calcium HMB to help build, recover, and preserve muscle. This product targets growing consumer interest in muscle...
In 2026, both Medtronic and Abbott stocks have declined, altering their dividend yields and valuations. Medtronic now offers a higher dividend yield of 3.3% versus Abbott's 2.56%, making it more attractive for retirees needing income. Abbott, however...
